Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Br J Haematol ; 193(4): 750-760, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33650100

RESUMEN

Proteasome inhibitors have been associated with thrombotic microangiopathy (TMA) - a group of disorders characterised by occlusive microvascular thrombosis causing microangiopathic haemolytic anaemia, thrombocytopenia and end-organ damage. To date, carfilzomib-associated TMA has predominantly been described in relapsed/refractory myeloma patients. We report eight patients with newly diagnosed myeloma who experienced TMA events while receiving carfilzomib on the phase II CARDAMON trial. The first three occurred during maintenance single-agent carfilzomib, two occurred at induction with carfilzomib given with cyclophosphamide and dexamethasone (KCd) and three occurred during KCd consolidation. At TMA presentation 6/8 were hypertensive; 7/8 had acute kidney injury and in three, renal impairment persisted after resolution of TMA in other respects. The mechanism of carfilzomib-associated TMA remains unclear, though patients with known hypertension seem particularly susceptible. Given the first three cases occurred during maintenance after a longer than five-week treatment break, a protocol amendment was instituted with: aggressive hypertension management, carfilzomib step-up dosing (20 mg/m2 on day 1) at start of maintenance before dose escalation to 56 mg/m2 maximum, and adding 10 mg dexamethasone as premedication to maintenance carfilzomib infusions. No further TMA events occurred during maintenance following this amendment and the TMA incidence reduced from 4·2 to 1·6 per 1 000 patient cycles.


Asunto(s)
Lesión Renal Aguda , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Mieloma Múltiple , Microangiopatías Trombóticas , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/epidemiología , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Dexametasona/administración & dosificación , Dexametasona/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/epidemiología , Oligopéptidos/administración & dosificación , Oligopéptidos/efectos adversos , Microangiopatías Trombóticas/inducido químicamente , Microangiopatías Trombóticas/epidemiología
3.
Gut ; 60(5): 666-70, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21131631

RESUMEN

BACKGROUND: Characteristic pancreatic duct changes on endoscopic retrograde pancreatography (ERP) have been described in autoimmune pancreatitis (AIP). The performance characteristics of ERP to diagnose AIP were determined. METHODS: The study was done in two phases. In phase I, 21 physicians from four centres in Asia, Europe and the USA, unaware of the clinical data or diagnoses, reviewed 40 preselected ERPs of patients with AIP (n=20), chronic pancreatitis (n=10) and pancreatic cancer (n=10). Physicians noted the presence or absence of key pancreatographic features and ranked the diagnostic possibilities. For phase II, a teaching module was created based on features found most useful in the diagnosis of AIP by the four best performing physicians in phase I. After a washout period of 3 months, all physicians reviewed the teaching module and reanalysed the same set of ERPs, unaware of their performance in phase I. RESULTS: In phase I the sensitivity, specificity and interobserver agreement of ERP alone to diagnose AIP were 44, 92 and 0.23, respectively. The four key features of AIP identified in phase I were (i) long (>1/3 the length of the pancreatic duct) stricture; (ii) lack of upstream dilatation from the stricture (<5 mm); (iii) multiple strictures; and (iv) side branches arising from a strictured segment. In phase II the sensitivity (71%) of ERP significantly improved (p<0.05) without a significant decline in specificity (83%) (p>0.05); the interobserver agreement was fair (0.40). CONCLUSIONS: The ability to diagnose AIP based on ERP features alone is limited but can be improved with knowledge of some key features.


Asunto(s)
Enfermedades Autoinmunes/diagnóstico por imagen , Colangiopancreatografia Retrógrada Endoscópica/métodos , Pancreatitis Crónica/diagnóstico por imagen , Algoritmos , Colangiopancreatografia Retrógrada Endoscópica/normas , Competencia Clínica , Diagnóstico Diferencial , Educación Médica Continua/métodos , Humanos , Cooperación Internacional , Neoplasias Pancreáticas/diagnóstico , Radiología/educación , Sensibilidad y Especificidad
4.
BMJ Open ; 12(11): e063037, 2022 11 17.
Artículo en Inglés | MEDLINE | ID: mdl-36396306

RESUMEN

INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (minimal residual disease (MRD)-positive) postautologus stem cell transplant (ASCT), fare worse compared with those who do not (MRD-negative). Research is required to determine whether a risk-adapted approach post-ASCT could further improve patient outcomes. METHODS: RADAR is a UK, multicentre, risk-adapted, response-guided, open-label, randomised controlled trial for transplant-eligible newly diagnosed multiple myeloma patients, using combinations of lenalidomide (R), cyclophosphamide (Cy), bortezomib (Bor), dexamethasone (D) and isatuximab (Isa).Participants receive RCyBorD(x4) induction therapy, followed by high-dose melphalan and ASCT. Post-ASCT, there are three pathways as follows:A phase III discontinuation design to assess de-escalating therapy in standard-risk MRD-negative patients. Participants receive 12 cycles of Isa maintenance. Those who remain MRD-negative are randomised to either continue or stop treatment.A phase II/III multiarm multistage design to test treatment strategies for treatment escalation in standard-risk MRD-positive patients. Participants are randomised to either; R, RBorD(x4) +R, RIsa, or RBorIsaD(x4) + RIsa.A phase II design to assess the activity of intensive treatment strategies in high-risk patients. Participants are randomised to RBorD(x4) +R or RBorIsaD(x4) + RIsa.1400 participants will be registered to allow for 500, 450 and 172 participants in each pathway. Randomisations are equal and treatment is given until disease progression or intolerance. ETHICS AND DISSEMINATION: Ethical approval was granted by the London-Central Research Ethics Committee (20/LO/0238) and capacity and capability confirmed by the appropriate local research and development department for each participating centre prior to opening recruitment. Participant informed consent is required before trial registration and reconfirmed post-ASCT. Results will be disseminated by conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: ISCRTN46841867.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Mieloma Múltiple , Humanos , Mieloma Múltiple/tratamiento farmacológico , Trasplante Autólogo , Trasplante de Células Madre Hematopoyéticas/métodos , Trasplante de Células Madre/efectos adversos , Neoplasia Residual/etiología , Reino Unido , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Multicéntricos como Asunto , Ensayos Clínicos Fase II como Asunto
5.
Biomed Phys Eng Express ; 7(3)2021 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-33657539

RESUMEN

Geometric distortions in magnetic resonance can introduce significant uncertainties into applications such as radiotherapy treatment planning and need to be assessed as part of a comprehensive quality assurance program. We report the design, fabrication, and imaging of a custom 3D printed unibody MR distortion phantom along with quantitative image analysis.Methods: The internal cavity of the phantom is an orthogonal three-dimensional planar lattice, composed of 3 mm diameter rods spaced equidistantly at a 20 mm centre-centre offset repeating along the X, Y, and Z axes. The phantom featured an overall length of 308.5 mm, a width of 246 mm, and a height of 264 mm with lines on the external surface for phantom positioning matched to external lasers. The MR phantom was 3D printed in Nylon-12 using an advancement on traditional selective laser sintering (SLS) (HP Jet Fusion 3D-4200 machine). The phantom was scanned on a Toshiba Aquilion CT scanner to check the integrity of the 3D print and correct for any resultant issues. The phantom was then filled with NiSO4solution and scanned on a 3T PET-MR Siemens scanner for selected T1 and T2 sequences, from which distortion vectors were generated and analysed using in-house software written in Python.Results: All deviations of the node positions from the print design were less than 1 mm, with an average displacement of 0.228 mm. The majority of the deviations were smaller than the 0.692 mm pixel size for this dataset.Conclusion: A customised 3D printed MRI-phantom was successfully printed and tested for assessing geometric distortion on MRI scanners. 3D printed phantoms can be considered for clinics wishing to assess geometric distortions under specific conditions, but require resources for design, fabrication, commissioning, and verification.


Asunto(s)
Imagen por Resonancia Magnética , Programas Informáticos , Imagen por Resonancia Magnética/métodos , Fantasmas de Imagen , Impresión Tridimensional
6.
Breathe (Sheff) ; 15(2): 108-109, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31191720

RESUMEN

A patient shares his experiences of living with respiratory problems, including his diagnosis with allergic bronchopulmonary aspergillosis http://ow.ly/AyNI30oc4US.

SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda